Physiomics secures new contract from existing pharma client

Physiomics, a specialist in mathematical modelling and data science for drug development and personalised medicine, announced on Tuesday that it has secured a new contract worth £65,000 from an existing large pharmaceutical client.

The AIM-traded company said the project would involve updating two previously-developed models with newly-generated clinical data, to assist in dosing and scheduling decisions for oncology combination therapies.

It said the models were based on its proprietary Virtual Tumour platform, which simulates tumour growth and treatment responses to help optimise cancer therapy regimens.

By incorporating the latest clinical data, the firm was aiming to improve the predictive accuracy of the models, potentially enhancing the effectiveness of the client's cancer treatments.

The project was expected to be completed within the current calendar year.

“We are delighted to have been awarded this new contract with one of our existing clients,” said chief executive officer Dr Peter Sargent.

“This win is testament to the quality and impact of the services we provide and the longevity of our client relationships.”

At 1240 BST, shares in Physiomics were down 1.33% at 0.67p.

Reporting by Josh White for Sharecast.com.